BACKGROUND: Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge. METHODS: Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH. RESULTS: During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking. CONCLUSIONS: The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
RCT Entities:
BACKGROUND: Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge. METHODS: Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH. RESULTS: During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking. CONCLUSIONS: The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
Authors: Kenneth H Levin; Marc L Copersino; Stephen J Heishman; Fang Liu; Deanna L Kelly; Douglas L Boggs; David A Gorelick Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Carl L Hart; Margaret Haney; Amie S Ward; Marian W Fischman; Richard W Foltin Journal: Drug Alcohol Depend Date: 2002-08-01 Impact factor: 4.492
Authors: Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis Journal: Clin Chem Date: 2009-10-15 Impact factor: 8.327
Authors: Mateus M Bergamaschi; Erin L Karschner; Robert S Goodwin; Karl B Scheidweiler; Jussi Hirvonen; Regina H C Queiroz; Marilyn A Huestis Journal: Clin Chem Date: 2013-03 Impact factor: 8.327
Authors: Margaret Haney; Carl L Hart; Suzanne K Vosburg; Jennifer Nasser; Andrew Bennett; Carlos Zubaran; Richard W Foltin Journal: Neuropsychopharmacology Date: 2004-01 Impact factor: 7.853
Authors: Ryan Vandrey; Maxine L Stitzer; Miriam Z Mintzer; Marilyn A Huestis; Jeannie A Murray; Dayong Lee Journal: Drug Alcohol Depend Date: 2012-08-22 Impact factor: 4.492
Authors: Ryan Vandrey; Evan S Herrmann; John M Mitchell; George E Bigelow; Ronald Flegel; Charles LoDico; Edward J Cone Journal: J Anal Toxicol Date: 2017-03-01 Impact factor: 3.367
Authors: David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney Journal: J Anal Toxicol Date: 2017-05-01 Impact factor: 3.367
Authors: Dayong Lee; Mateus M Bergamaschi; Garry Milman; Allan J Barnes; Regina H C Queiroz; Ryan Vandrey; Marilyn A Huestis Journal: J Anal Toxicol Date: 2015-10 Impact factor: 3.367
Authors: Dayong Lee; Ryan Vandrey; Damodara R Mendu; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis Journal: Drug Test Anal Date: 2014-09-14 Impact factor: 3.345
Authors: Evan S Herrmann; Edward J Cone; John M Mitchell; George E Bigelow; Charles LoDico; Ron Flegel; Ryan Vandrey Journal: Drug Alcohol Depend Date: 2015-04-06 Impact factor: 4.492
Authors: Joseph E Rower; Amber D King; Diana Wilkins; Jacob Wilkes; Venkata Yellepeddi; Luke Maese; Richard S Lemons; Jonathan E Constance Journal: J Adolesc Young Adult Oncol Date: 2020-07-14 Impact factor: 2.223